Advances in the research of inhibitors of enzymes of bacterial peptidoglycan biosynthesis
10.16438/j.0513-4870.2016-0902
- VernacularTitle:靶向细菌肽聚糖合成酶抑制剂的研究进展
- Author:
Fan LIU
1
;
Hao-yi MENG
1
;
Zheng-yang SUN
1
;
Dan-yang LI
2
;
Yuan-yuan JIN
2
;
Zhao-yong YANG
2
;
Shao-jie WU
3
;
Jing CHEN
1
Author Information
1. School of Basic Medical Sciences, North China University of Science and Technology, Tangshan 063000, China
2. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
3. HuaiHai Insititute of Technology, Lianyungang 222000, China
- Publication Type:REVIEWS
- Keywords:
peptidoglycan;
antibiotics;
Mur enzyme;
enzyme inhibitor;
drug discovery
- From:
Acta Pharmaceutica Sinica
2017;52(3):362-370
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, owing to the abuse of antibiotics, the widespread of resistant bacterial strains became a serious threat to public health. This status demands development of new antibacterial agents with novel mechanisms of action. The reason for the limited new antibacterials is the small number of effective therapeutic targets, which cannot meet the current needs for the multiple drug-resistant treatment. Screening for new targets is the key step in the development of novel antibacterial agents. Peptidoglycan is the main component of the cell wall of bacteria, which is essential for survival of pathogenic bacteria. Within the biochemical pathway for peptidoglycan biosynthes is the Murligases, described in this review as highly potential targets for the development of new classes of antibacterial agents. This review provides an in-depth insight into the recent developments in the field of inhibitors of the Mur enzymes (MurA-F). Moreover, the reasons for the lack of candidate inhibitors and the challenges to overcome the hurdles are also discussed.
